Topas Therapeutics, which is exploiting University of Hamburg research, has pocketed $26m in its series B round.

Topas Therapeutics, a Germany-based developer of treatments for autoimmune diseases based on research at University of Hamburg, closed a €22m ($26m) series B round yesterday co-led by Vesalius BioCapital III and BioMedPartners. All existing shareholders – EMBL Ventures, the investment arm of European Molecular Biology Laboratory, commercialisation firm Epidarex Capital, drug discovery company Evotec, pharmaceutical…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.